Edwards Lifesciences is a medical device company located in California, United States, which is part of the Healthcare sector, and is traded under the ticker EW on the NYSE exchange.
Edwards Lifesciences stock last closed at $82.45, down 1.23% from the previous day, and has increased 23.04% in one year. It has overperformed other stocks in the Medical Devices industry by 0.57 percentage points. Edwards Lifesciences stock is currently +27.06% from its 52-week low of $64.89, and -5.33% from its 52-week high of $87.09.
At the moment, there are 587.1M shares of EW outstanding. The market value of EW is $48.41B. In the last 24 hours, 11.51M EW shares were traded.
You will need an online brokerage account in order to access the NYSE market and buy EW shares.
Based on our analysis, eToro is the best brokerage. Here's why:
Get $10 towards your stock purchase by creating an account with eToro now. This offer is only for US users.
Open eToro AccountNow that you've picked the right brokerage, you'll need to fill out some personal details so you are able to buy EW stock today.
Now that you've created your account on one of the most highly reviewed stock market apps, you need to deposit funds:
Check out the walkthrough below if you need help transferring funds into your new brokerage account.
Once you have chosen the best place to buy Edwards Lifesciences stock, it's absolutely critical to analyze their stock prior to buying, so you actually comprehend the risk and opportunity.
WallStreetZen was built to help average investors do more in-depth fundamental analysis quickly.
You can view all of the due diligence checks on EW's stock page.
You can use a variety of different financial metrics, analyses, models, and charts to gauge EW's fair value.
Using relative valuations ratios:
You can do more valuation analysis on EW's stock here.
Out of 16 Wall Street analysts who give recommendations on EW, the consensus analyst rating on EW is a Buy
Please note that analyst forecasts are not recommendations, nor are they financial advice.
Shagun Singh, a bottom 14% analyst from RBC Capital maintains EW with a buy rating and raises their EW price target from $89.00 to $95.00, on Oct 31, 2025.
Rick Wise, a top 10% analyst from Stifel Nicolaus maintains EW with a strong buy rating and raises their EW price target from $85.00 to $95.00, on Oct 31, 2025.
Vijay Kumar, a bottom 4% analyst from Evercore ISI Group maintains EW with a buy rating and raises their EW price target from $88.00 to $92.00, on Oct 31, 2025.
Anthony Petrone, a top 6% analyst from Mizuho maintains EW with a buy rating and raises their EW price target from $90.00 to $100.00, on Oct 31, 2025.
Matthew Taylor, a top 16% analyst from Jefferies upgrades EW to a strong buy rating and raises their EW price target from $80.00 to $98.00, on Oct 29, 2025.
Jefferies's Matthew Taylor upgraded their rating on Edwards Lifesciences (NYSE: EW) from Hold to Strong Buy on 2025/10/29. The analyst also raised their price target by 22.5% from $80 to $98.
Edwards Lifesciences will report its Q3 2025 earnings on 2025/10/30.
According to Taylor, the company had a "stellar" Transcatheter Cardiovascular Therapeutics conference with high-frequency data showing that TAVR (Transcatheter Aortic Valve Replacement) growth is accelerating.
The analyst believes that the 7-year data from Edwards' Phase 3 gives hope for the long-term viability of TAVR and may lead to a rise in the number of low-risk patients who undergo implantation.
Further, the analyst thinks that the company's improved Evoque real-world data was a "positive surprise" and has the potential to stimulate the market.
You can dive deeper into what analysts are forecasting on the Edwards Lifesciences stock forecast page.
Last year, EW earnings were $4.15B. Over the last five year, EW's earnings have grown by 42.49% per year. This was faster than the Medical Devices industry average of 18.43%.
Last year, EW revenue was $5.69B. In the past 5 year, EW's revenue has increased by 5.64% per year. This was slower than the Medical Devices industry average of 10.65%.
Dive into EW's earnings and revenue performance here.
Over the past 12 months, executives and large shareholders at EW have sold more shares than they have bought.
Wayne Markowitz, CVP JAPAC of EW, was the latest EW insider to sell. They sold $50,420.50 worth of EW shares on Sep 14, 2025.
Dig into more about who owns EW shares here.
No, Edwards Lifesciences doesn't provide an income stream by paying out dividends.
One of the biggest reasons eToro is our top-rated brokerage is because of its social trading community.
Click below to find out what other community members have to say.
You have two primary order types:
Hit the Open button and eToro will execute your order.
If you need additional info about buying stocks on eToro, watch the how to video below:
Now that you own some EW shares, you'll want to keep up with your new company.
Make a watchlist to get notified of important updates regarding your EW stock.
To summarize, here are the 6 steps to buy Edwards Lifesciences stock:
If you are looking for a place to buy stocks, eToro is our recommended option.
Get Started with eToro TodayIf you want to keep an eye on your investment in Edwards Lifesciences, create a watchlist today.